EUVIMEDEUVIMED entdecken
Crossref

Genetic testing in a national cohort of adults with chronic kidney disease of unknown origin

Amber de Haan iD, Mark Eijgelsheim, Liffert Vogt, Ewout J Hoorn iD, Joris I Rotmans, Gijs Fortrie, Roos F J Marsman, Tonia C Rothuizen, H Siebe Spijker, Laura R Claus iD, Constantijn J A M Konings, Femke Waanders und 7 weitere

Nephrology Dialysis Transplantation · 30.05.2025 · 40 (6) · 1225-1233

DOI: 10.1093/ndt/gfae270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 19.11.2024. Verfasst von Amber de Haan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Genetic Testing, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Sanofi Genzyme, Dutch Ministry of Economic Affairs and Climate Policy, Dutch Kidney Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease (CKD) remains unexplained in at least 20% of patients. Massively parallel sequencing (MPS) can be a valuable diagnostic tool in patients with unexplained CKD, but prospective data from routine clinical practice are limited. We aimed to determine the diagnostic yield and relevance of MPS-based gene panel testing in patients with unexplained CKD in a real-world context. We additionally examined barriers to implementation of genetic testing.

Methods

In this prospective cohort study, we recruited patients with unexplained CKD (estimated glomerular filtration rate <60 ml/min/1.73 m2 without underlying clinical diagnosis) with onset at <50 years of age who underwent MPS-based multigene panel testing from 11 academic and non-academic hospitals across the Netherlands. In patients with a (likely) pathogenic variant, we verified that the variant likely explained the clinical phenotype. A nationwide online survey was sent to all Dutch nephrologists and residents to investigate potential barriers for gene panel testing.

Results

A diagnostic variant was identified in 59/340 participants (17%). Most common diagnostic variants were in NPHP1 (13 patients), COL4A3 (12 patients), COL4A4 (5 patients), COL4A5 (6 patients) and PAX2 (5 patients). A genetic diagnosis led to at least one clinical consequence in 73% of patients. Main barriers reported by Dutch nephrologists (N = 71) included genetic illiteracy (53%), difficulties with test selection (51%) and a lack of time (43%).

Conclusions

MPS-based multigene panel testing yielded a genetic diagnosis in 17% of patients with unexplained CKD. Our findings support the relevance of MPS in the diagnostic workup of adults with unexplained CKD with onset at <50 years of age. Additionally, our results underline the need to improve genetic education among nephrologists to better the implementation of MPS-based diagnostic testing in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingRenal Insufficiency, ChronicHumansMaleFemaleProspective StudiesMiddle AgedAdultNetherlandsGlomerular Filtration RateFollow-Up StudiesPrognosisCohort StudiesHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

chronic kidney diseasediagnostic yieldexome sequencinggeneticsmassively parallel sequencing

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Internal Medicine, Section of Nephrology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of internal Medicine, Division of Nephrology, Groene Hart Hospital, Gouda, The Netherlands.
  • Department of Internal Medicine, Division of Nephrology, Rijnstate Hospital, Arnhem, The Netherlands.

ORCID-Profile: Amber de Haan, Ewout J Hoorn, Laura R Claus, Martin H de Borst

Förderung

  • Sanofi Genzyme
  • Dutch Ministry of Economic Affairs and Climate Policy
  • Dutch Kidney Foundation

Zitieren

APA

de Haan, A., Eijgelsheim, M., Vogt, L., Hoorn, E. J., Rotmans, J. I., Fortrie, G., Marsman, R. F. J., Rothuizen, T. C., Spijker, H. S., Claus, L. R., Konings, C. J. A. M., Waanders, F., Doornebal, J., Kramer, A. B., Adema, A. Y., van der Zwaag, B., van Eerde, A. M., Knoers, N. V. A. M., & de Borst, M. H. (2025). Genetic testing in a national cohort of adults with chronic kidney disease of unknown origin. Nephrology Dialysis Transplantation, 40(6), 1225-1233. https://doi.org/10.1093/ndt/gfae270

Vancouver

de Haan A, Eijgelsheim M, Vogt L, Hoorn EJ, Rotmans JI, Fortrie G, et al. Genetic testing in a national cohort of adults with chronic kidney disease of unknown origin. Nephrology Dialysis Transplantation. 2025;40(6):1225-1233. doi:10.1093/ndt/gfae270

BibTeX
@article{deHaan2025,
  author = {de Haan, Amber and Eijgelsheim, Mark and Vogt, Liffert and Hoorn, Ewout J and Rotmans, Joris I and Fortrie, Gijs and Marsman, Roos F J and Rothuizen, Tonia C and Spijker, H Siebe and Claus, Laura R and Konings, Constantijn J A M and Waanders, Femke and Doornebal, Joan and Kramer, Andrea B and Adema, Aaltje Y and van der Zwaag, Bert and van Eerde, Albertien M and Knoers, Nine V A M and de Borst, Martin H},
  title = {Genetic testing in a national cohort of adults with chronic kidney disease of unknown origin},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {6},
  pages = {1225--1233},
  doi = {10.1093/ndt/gfae270}
}
Kostenlos starten →